Human Embryonic Stem Cells vs Human Induced Pluripotent Stem Cells for Cardiac Repair

Canadian Journal of Cardiology

Volumn 30, Issue 11, 2014, Pages 1279-1287

  Barad, Lili ^a   Schick, Revital ^a   Zeevi Levin, Naama ^a   Itskovitz Eldor, Joseph ^a   Binah, Ofer ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DIFFERENTIATION; CELL HETEROGENEITY; EMBRYONIC STEM CELL; EXCITATION CONTRACTION COUPLING; GENETICS; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART TRANSPLANTATION; HUMAN; IMMUNOGENICITY; IN VIVO STUDY; LEFT VENTRICULAR ASSIST DEVICE; MEDICAL ETHICS; NONHUMAN; ORGAN DONOR; PLURIPOTENT STEM CELL; REVIEW; STEM CELL TRANSPLANTATION; TERATOMA; TISSUE REGENERATION; HEART DISEASES; PATHOLOGY; PROCEDURES; TRANSPLANTATION;

CELL DIFFERENTIATION; EMBRYONIC STEM CELLS; HEART DISEASES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MYOCYTES, CARDIAC; STEM CELL TRANSPLANTATION;

EID: 84908468829     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.06.023     Document Type: Review

References (79)

1. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127:e6-e245.
2. van den Heuvel N.H., van Veen T.A., Lim B., Jonsson M.K. Lessons from the heart: mirroring electrophysiological characteristics during cardiac development to invitro differentiation of stem cell derived cardiomyocytes. JMol Cell Cardiol 2014, 67:12-25.
3. Germanguz I., Sedan O., Zeevi-Levin N., et al. Molecular characterization and functional properties of cardiomyocytes derived from human inducible pluripotent stem cells. JCell Mol Med 2011, 15:38-51.
4. He J.Q., Ma Y., Lee Y., Thomson J.A., Kamp T.J. Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ Res 2003, 93:32-39.
5. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
6. Takahashi K., Tanabe K., Ohnuki M., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
7. Blazeski A., Zhu R., Hunter D.W., Weinberg S.H., Zambidis E.T., Tung L. Cardiomyocytes derived from human induced pluripotent stem cells as models for normal and diseased cardiac electrophysiology and contractility. Prog Biophys Mol Biol 2012, 110:166-177.
8. Gherghiceanu M., Barad L., Novak A., et al. Cardiomyocytes derived from human embryonic and induced pluripotent stem cells: comparative ultrastructure. JCell Mol Med 2011, 15:2539-2551.
9. Mallon B.S., Hamilton R.S., Kozhich O.A., et al. Comparison of the molecular profiles of human embryonic and induced pluripotent stem cells of isogenic origin. Stem Cell Res 2014, 12:376-386.
10. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., et al. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-1147.
11. Novak A., Shtrichman R., Germanguz I., et al. Enhanced reprogramming and cardiac differentiation of human keratinocytes derived from plucked hair follicles, using a single excisable lentivirus. Cell Reprogram 2010, 12:665-678.
12. Haase A., Olmer R., Schwanke K., et al. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell 2009, 5:434-441.
13. Hockemeyer D., Soldner F., Beard C., et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 2009, 27:851-857.
14. Ma N., Liao B., Zhang H., et al. Transcription activator-like effector nuclease (TALEN)-mediated gene correction in integration-free beta-thalassemia induced pluripotent stem cells. JBiol Chem 2013, 288:34671-34679.
15. Cao J., Li X., Lu X., et al. Cells derived from iPSC can be immunogenic-yes or no?. Protein Cell 2014, 5:1-3.
16. Zhao T., Zhang Z.N., Rong Z., Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011, 474:212-215.
17. Kim K., Doi A., Wen B., et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010, 467:285-290.
18. Lister R., Pelizzola M., Kida Y.S., et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011, 471:68-73.
19. Lui K.O., Bu L., Li R.A., Chan C.W. Pluripotent stem cell-based heart regeneration: from the developmental and immunological perspectives. Birth Defects Res C Embryo Today 2012, 96:98-108.
20. Kaneko S., Yamanaka S. To be immunogenic, or not to be: that's the iPSC question. Cell Stem Cell 2013, 12:385-386.
21. Jia F., Wilson K.D., Sun N., et al. Anonviral minicircle vector for deriving human iPS cells. Nat Methods 2010, 7:197-199.
22. Anoke-Danso F., Trivedi C.M., Juhr D., et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 2011, 8:376-388.
23. Miyosi N., Ishii H., Nagano H., et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 2011, 8:633-638.
24. Zhu S., Li W., Zhou H., et al. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell 2010, 7:651-655.
25. Pasha Z., Haider H., Ashraf M. Efficient non-viral reprogramming of myoblasts to stemness with a single small molecule to generate cardiac progenitor cells. PLoS One 2011, 6:e23667.
26. Taylor C.J., Bolton E.M., Bradley J.A. Immunological considerations for embryonic and induced pluripotent stem cell banking. Philos Trans R Soc Lond B Biol Sci 2011, 366:2312-2322.
27. Bernstein H.S., Srivastava D. Stem cell therapy for cardiac disease. Pediatr Res 2012, 71:491-499.
28. Reinecke H., Minami E., Zhu W.Z., Laflamme M.A. Cardiogenic differentiation and transdifferentiation of progenitor cells. Circ Res 2008, 103:1058-1071.
29. Parsons X.H. Direct conversion of pluripotent human embryonic stem cells under defined culture conditions into human neuronal or cardiomyocyte cell therapy derivatives. Methods Mol Biol 2014 Feb 6, [epub ahead of print].
30. Ye L., Zhang S., Greder L., et al. Effective cardiac myocyte differentiation of human induced pluripotent stem cells requires VEGF. PLoS One 2013, 8:e53764.
31. Zhang J., Klos M., Wilson G.F., et al. Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: the matrix sandwich method. Circ Res 2012, 111:1125-1136.
32. Laflamme M.A., Chen K.Y., Naumova A.V., et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007, 25:1015-1024.
33. Lian X., Zhang J., Azarin S.M., et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions. Nat Protoc 2013, 8:162-175.
34. Lee M.O., Moon S.H., Jeong H.C., et al. Inhibition of pluripotent stem cell-derived teratoma formation by small molecules. Proc Natl Acad Sci U S A 2013, 110:E3281-E3290.
35. Anderson D., Self T., Mellor I.R., et al. Transgenic enrichment of cardiomyocytes from human embryonic stem cells. Mol Ther 2007, 15:2027-2036.
36. Xu X.Q., Zweigerdt R., Soo S.Y., et al. Highly enriched cardiomyocytes from human embryonic stem cells. Cytotherapy 2008, 10:376-389.
37. Hattori F., Chen H., Yamashita H., et al. Nongenetic method for purifying stem cell-derived cardiomyocytes. Nat Methods 2010, 7:61-66.
38. Tohyama S., Hattori F., Sano M., et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 2013, 12:127-137.
39. Dubois N.C., Craft A.M., Sharma P., et al. SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat Biotechnol 2011, 29:1011-1018.
40. Ramos C.A., Asgari Z., Liu E., et al. An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells 2010, 28:1107-1115.
41. 2+ handling and the role of sarcoplasmic reticulum in the contraction. Stem Cells 2006, 2:236-245.
42. Sedan O., Dolnikov K., Zeevi-Levin N., et al. 1,4,5-Inositol trisphosphate-operated intracellular Ca(2+) stores and angiotensin-II/endothelin-1 signaling pathway are functional in human embryonic stem cell-derived cardiomyocytes. Stem Cells 2008, 26:3130-3138.
43. Zeevi-Levin N., Itskovitz-Eldor J., Binah O. Functional properties of human embryonic stem cell-derived cardiomyocytes. Crit Rev Eukaryot Gene Expr 2010, 20:51-59.
44. Zeevi-Levin N., Itskovitz-Eldor J., Binah O. Cardiomyocytes derived from human pluripotent stem cells for drug screening. Pharmacol Ther 2012, 134:180-188.
45. Zhang J., Wilson G.F., Soerens A.G., et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009, 104:e30-e41.
46. Ma J., Guo L., Fiene S.J., et al. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol 2011, 301:H2006-H2017.
47. Lee Y.K., Ng K.M., Lai W.H., et al. Calcium homeostasis in human induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Rev 2011, 7:976-986.
48. Otsuji T.G., Minami I., Kurose Y., et al. Progressive maturation in contracting cardiomyocytes derived from human embryonic stem cells: qualitative effects on electrophysiological responses to drugs. Stem Cell Res 2010, 4:201-213.
49. Yang X., Pabon L., Murry C.E. Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes. Circ Res 2014, 114:511-523.
50. Tulloch N.L., Muskheli V., Razumova M.V., et al. Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res 2011, 109:47-59.
51. Mihic A., Li J., Miyagi Y., et al. The effect of cyclic stretch on maturation and 3D tissue formation of human embryonic stem cell-derived cardiomyocytes. Biomaterials 2014, 35:2798-2808.
52. Govoni M., Muscari C., Guarnieri C., Giordano E. Mechanostimulation protocols for cardiac tissue engineering. Biomed Res Int 2013, 2013:918640.
53. Zhu W.Z., Xie Y., Moyes K.W., et al. Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells. Circ Res 2010, 107:776-786.
54. Zhang Q., Jiang J., Han P. Direct differentiation of atrial and ventricular myocytes from human embryonic stem cells by alternating retinoid signals. Cell Res 2011, 21:579-587.
55. Xu H., Yi B.A., Wu H., et al. Highly efficient derivation of ventricular cardiomyocytes from induced pluripotent stem cells with a distinct epigenetic signature. Cell Res 2012, 22:142-154.
56. Emmert M.Y., Hitchcock R.W., Hoerstrup S.P. Cell therapy, 3D culture systems and tissue engineering for cardiac regeneration. Adv Drug Deliv Rev 2014, 69-70:254-269.
57. Robey T.E., Saiget M.K., Reinecke H., Murry C.E. Systems approaches to preventing transplanted cell death in cardiac repair. JMol Cell Cardiol 2008, 45:567-581.
58. Garbern J.C., Lee R.T. Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell 2013, 12:689-698.
59. du Pré B.C., Doevendans P.A., van Laake L.W. Stem cells for cardiac repair: an introduction. JGeriatr Cardiol 2013, 10:186-197.
60. Vunjak-Novakovic G., Lui K.O., Tandon N., Chien K.R. Bioengineering heart muscle: a paradigm for regenerative medicine. Annu Rev Biomed Eng 2011, 13:245-267.
61. Hirt M.N., Hansen A., Eschenhagen T. Cardiac tissue engineering: state of the art. Circ Res 2014, 114:354-367.
62. Radisic M., Christman K.L. Materials science and tissue engineering: repairing the heart. Mayo Clin Proc 2013, 88:884-898.
63. Wall S.T., Yeh C.C., Tu R.Y., Mann M.J., Healy K.E. Biomimetic matrices for myocardial stabilization and stem cell transplantation. JBiomed Mater Res A 2010, 95:1055-1066.
64. Zhang M., Methot D., Poppa V., et al. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. JMol Cell Cardiol 2001, 33:907-921.
65. Kehat I., Khimovich L., Caspi O., et al. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol 2004, 22:1282-1289.
66. Shiba Y., Fernandes S., Zhu W.Z., et al. Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature 2012, 489:322-325.
67. Leor J., Gerecht S., Cohen S., et al. Human embryonic stem cell transplantation to repair the infarcted myocardium. Heart 2007, 93:1278-1284.
68. Kofidis T., Lebl D.R., Swijnenburg R.J., et al. Allopurinol/uricase and ibuprofen enhance engraftment of cardiomyocyte-enriched human embryonic stem cells and improve cardiac function following myocardial injury. Eur J Cardiothorac Surg 2006, 29:50-55.
69. van Laake L.W., Passier R., Monshouwer-Kloots J., et al. Human embryonic stem cell-derived cardiomyocytes survive and mature in the mouse heart and transiently improve function after myocardial infarction. Stem Cell Res 2007, 1:9-24.
70. Caspi O., Lesman A., Basevitch Y., et al. Tissue engineering of vascularized cardiac muscle from human embryonic stem cells. Circ Res 2007, 100:263-272.
71. Lesman A., Habib M., Caspi O., et al. Transplantation of a tissue-engineered human vascularized cardiac muscle. Tissue Eng Part A 2010, 16:115-125.
72. Emmert M.Y., Wolint P., Wickboldt N., et al. Human stem cell-based three-dimensional microtissues for advanced cardiac cell therapies. Biomaterials 2013, 34:6339-6354.
73. Wollert K.C., Meyer G.P., Lotz J. Intracoronary autologous bone-marrow cell clinical trial. Lancet 2004, 364:141-148.
74. Lian W.S., Cheng W.T., Cheng C.C. Invivo therapy of myocardial infarction with mesenchymal stem cells modified with prostaglandin I synthase gene improves cardiac performance in mice. Life Sci 2011, 88:455-464.
75. Mias C., Lairez O., Trouche E. Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. Stem Cells 2009, 27:2734-2743.
76. Carpenter L., Carr C., Yang C.T., et al. Efficient differentiation of human induced pluripotent stem cells generates cardiac cells that provide protection following myocardial infarction in the rat. Stem Cells Dev 2012, 21:977-986.
77. Kawamura M., Miyagawa S., Miki K., et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation 2012, 126:S29-S37.
78. Kawamura M., Miyagawa S., Fukushima S., et al. Enhanced survival of transplanted human induced pluripotent stem cell-derived cardiomyocytes by the combination of cell sheets with the pedicled omental flap technique in a porcine heart. Circulation 2013, 128:S87-S94.
79. Harding J., Mirochnitchenko O. Preclinical studies for induced pluripotent stem cell-based therapeutics. JBiol Chem 2014, 289:4585-4593.